反安慰剂效应对新药临床试验疗效评估的影响与应对建议

来源 :中华中医药杂志 | 被引量 : 0次 | 上传用户:asdf200201
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
对一项新药临床试验进行回顾性研究发现,知情同意导致反安慰剂效应,严重干扰疗效评估;功能性指标更易受反安慰剂效应的干扰,而客观指标则较为稳定。建议严格选择应用安慰剂的适应症、使用客观指标判定疗效、采用基础治疗与加载试验、谨慎纳入人格缺陷者、暂时隐瞒等应对反安慰剂效应。 A retrospective study of a new drug clinical trial found that informed consent led to anti-placebo effects that severely disrupted the efficacy evaluation; functional indicators were more susceptible to anti-placebo effects and objective indicators were more stable. It is recommended to choose strictly placebo indications, the use of objective indicators to determine efficacy, the use of basic treatment and loading test, careful inclusion of personality defects, temporary concealment and other counter-placebo effect.
其他文献